Brief: Gilead Sciences Inc Amendment Provides Gilead With One Additional Seat On Arcus Board

Arcus Biosciences

29/01/2024 22:21

Jan 29 (Reuters) - Gilead Sciences Inc  GILD.O :
    * GILEAD SCIENCES INC: AMENDMENT PROVIDES GILEAD WITH ONE
ADDITIONAL SEAT ON ARCUS BOARD
    * GILEAD SCIENCES INC -  SEPARATE EQUITY INVESTMENT BY
GILEAD OF
$320 MILLION IN ARCUS COMMON STOCK AT $21.00 PER SHARE
    * GILEAD SCIENCES INC: GILEAD AND ARCUS ANNOUNCE AMENDED
COLLABORATION AND EQUITY INVESTMENT
    * GILEAD SCIENCES INC - ADDITIONAL EQUITY INVESTMENT OF
$320M,
RAISING GILEAD'S OWNERSHIP STAKE IN ARCUS TO 33%
    * GILEAD SCIENCES:CO,ARCUS REPRIORITIZED JOINT DOMVANALIMAB
DEVELOPMENT PROGRAM TO FOCUS ON POTENTIALLY ACCELERATING PHASE 3
STUDIES STAR-121, STAR-221
    * GILEAD SCIENCES INC - JOHANNA MERCIER, CHIEF COMMERCIAL
OFFICER
AT GILEAD SCIENCES, WILL JOIN ARCUS BOARD
    * GILEAD SCIENCES: PLANNED PHASE 3 FIRST-LINE STUDY IN
PANCREATIC
CANCER TO BE ARCUS INDEPENDENT STUDY
    * GILEAD SCIENCES INC: ADDITIONAL INVESTMENT BY GILEAD
EXTENDS
ARCUS' CASH RUNWAY INTO 2027
    * GILEAD SCIENCES- ADDITIONAL CHANGES DURING THIS
PRIORITIZATION
WILL INCLUDE DISCONTINUING FURTHER ENROLLMENT IN PHASE 3 ARC-10
STUDY

Source text for Eikon:  ID:nBw7D4T3da 
Further company coverage:  GILD.O 

 ((Reuters.Briefs@thomsonreuters.com;))